ナミキ商事株式会社 医薬品及び創薬化学品の専門商社

医薬品及び創薬化学品の専門商社

検索検索

新着情報News

【CUSABIO】Anti-Payload Antibodies

  • 2024/05/31
  • サプライヤニュース

新着情報一覧へ

If you are unable to see the message below, click here to view.

Antibody-drug conjugates (ADCs) are a novel class of anticancer drugs that combine monoclonal antibodies with small molecule toxins, offering high target specificity and cytotoxicity. Following ADC administration, the payload can undergo payload release resulting in an increase in unbound payload and changes in ADC components (i.e., DAR distribution). Therefore, quantitative analysis of the conjugated antibody and payload on the antibody in vivo is crucial for assessing ADC efficacy, evaluating payload exposure at the target site, and determining the significance of DAR distribution and changes in average DAR value for providing overall assessment of ADC stability.

CUSABIO introduces specialized tools for preclinical and clinical stage antibody-drug research - anti-Payload antibodies. These antibodies can be utilized for plasma/serum pharmacokinetic analysis of ADC drugs, determination of drug binding affinity, DAR value analysis, and evaluation of ADC drug efficacy.

Analysis Methods for Various Components of ADCs

Comprehensive bioanalytical methods, including ligand binding assays and liquid chromatography-tandem mass spectrometry (LC-MS/MS), are required for the biological analysis of ADCs, covering both large molecule and small molecule analysis. Anti-Payload antibodies play a crucial role in immunogenicity analysis within ADCs and are employed in bridging immunoassays(Bridging LBA) for immunogenicity analysis.

Analyte Type Description Typical analytical platforms
Total antibody Total antibody (conjugated or unconjugated) LBA, hybrid LC-MS/MS
Total ADC Total conjugated antibody (DAR > 1)OR/td> LBA
Total payload conjugated to antibody (DAR > 1) LBA hybrid LC-MS/MS
Unconjugated payload Payload not conjugated to antibody LC-MS/MS
Anti-drug antibodies (ADA) Antibodies directed against antibody components of ADC, linker, or drug (binding/neutralizing) LBA

Anti payload antibodies for ADC-Anti DXD

Figure. 1 DXD-the most promising payload for next-generation ADCs [1]

References: [1] Kumar, Seema, ed. An Introduction to Bioanalysis of Biopharmaceuticals. Vol. 57. Springer Nature, 2022.

Applications

Pharmacokinetic (PK) analysis
 
Qualitative analysis of ADC DAR values
 
Immunogenicity analysis
 
Preclinical and clinical stage antibody development for drug resistance

Product Advantages

   
High Purity

Purity validated to be over 90% through SDS-PAGE.

  High Sensitivity

Anti-DXD antibody activity verified through binding with leading ADC drug DS-8201, the activity was 4-5 times that of other companies.

  Expert Technical Team

Responsive within 24 hours for any pre-sales or after-sales inquiries.

Anti DXD mAb

Code Product Name Application
CSB-MA996977I1m DXD Monoclonal Antibody ELISA
CSB-MA996977I1m-B DXD Monoclonal Antibody, HRP conjugated ELISA
CSB-MA996977I2m DXD Monoclonal Antibody ELISA
CSB-MA996977I2m-B DXD Monoclonal Antibody, HRP conjugated ELISA
CSB-MA903890I1m MMAE&MMAF Monoclonal Antibody ELISA
CSB-MA943989I1m Eribulin Monoclonal Antibody ELISA

Supplemental Data

High purity verified by SEC-MALS and SDS-PAGE with Anti-DXD antibody
(Code: CSB-MA996977I2m)
 
High purity verified by SEC-MALS and SDS-PAGE with Anti-Eribulin Antibody
(Code: CSB-MA943989I1m)
 

The Mouse Anti-DXD Antibody (Code: CSB-MA996977I2m) has a purity of more than 90% as determined by SEC-MALS and SDS-PAGE.

 

The Mouse Anti-DXD Antibody (Code: CSB-MA943989I1m) has a purity of more than 98% as determined by SEC-MALS and SDS-PAGE.

The Binding Activity of Disitamab vedotin (Synonyms: RC48) with Anti-MMAE antibody
(Code: CSB-MA903890I1m)
 
The Binding Activity of T-DXd(DS-8201) with Anti-DXD antibody
(Code: CSB-MA996977I2m)
 

Activity: Measured by its binding ability in a functional ELISA. Immobilized Disitamab vedotin (Synonyms: RC48) at 2 μg/mL can bind Anti-MMAE antibody, the EC50 is 11.65 to 15.97 ng/mL.

 

Activity: Measured by its binding ability in a functional ELISA. Immobilized T-DXd(DS-8201) at 2 μg/mL can bind Anti-DXD antibody, the activity was 4-5 times that of other companies.

Customization Services

CUSABIO has developed a range of high-purity, high-sensitivity, and high-affinity anti-Payload antibodies that can be used for preclinical and clinical stage DAR value and PK analysis of ADC drugs. We offer customized anti-Payload antibody services to meet the personalized needs of our customers.

Kit

Protein

Antibody

Molecular Biology

CUSABIO TECHNOLOGY LLC

Postal Address:

7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA

Website: www.cusabio.com

© 2024 CUSABIO All Products For Research Use Only

CUSABIO(クサバイオ)社について

設立
2007年
社員数
700名
本社所在地
中国 武漢
URL
https://www.cusabio.com/

CUSABIO社は体外診断用試薬および原料、生物科学研究用試薬、生物科学研究サービスに特化した、
世界約80か国に代理店を置くバイオテクノロジーサプライヤーです。
当社には、博士号と修士号を取得した科学者で構成される研究開発チームがあり、従業員の 60% 以上が技術チームの出身で、うち 20% が博士号、50% が修士号を取得しております。
研究チームは国内の著名な機関から集まり、タンパク質、抗体、ELISA キットの開発に長年の経験を持っております。
製品は主に抗体やタンパク質、ペプチドがあり、どの製品も高品質で提供が可能です。

特徴
    • 6000m2を超えるR&Dセンター

ご不明点等ございましたら、お気軽にお問い合わせください。

お問い合わせ